Purpose: To analyze the expression of PTOV1 in high-grade prostatic intraepithelial neoplasia (HG-PIN) and to explore its usefulness to predict prostate cancer in patients with isolated HG-PIN in needle biopsy (prostate needle biopsy). Experimental Design: PTOV1expression in HG-PIN lesions from 140 patients was analyzed by immunohistochemistry in a semiquantitative manner (Histo-score). HG-PIN derived from 79 radical prostatectomies for prostate cancer and from 11 cistoprostatectomies for bladder cancer without prostate cancer were used as positive and negative controls, respectively. Fifty patients with HG-PIN without concomitant cancer at their first prostate needle biopsy were chosen as the study group. Patients were followed by a mean of 2.5 repeated prostate needle biopsies (1-5), during a mean period of 12.4 months (1-39). Results: PTOV1expression in HG-PIN from radical prostatectomies showed a significantly higher Histo-score (162.6) compared with specimens from cistoprostatectomies (67.0). In the study group, PTOV1 expression was significantly higher in samples with cancer in the follow-up (11 patients, 22%) compared with samples in which cancer was not detected (151.4 versus 94.6). PTOV1expression was the only independent predictor of cancer in the multivariate analysis and the area under the curve was 0.803 (95% confidence interval, 0.728-0.878). A threshold of 100 for PTOV1 expression provided 90.9% sensitivity, 51.3% specificity, 34.5% positive predictive value, and 95.2% negative predictive value. Conclusions: PTOV1 is overexpressed in HG-PIN associated with cancer and is a potential marker for studying the carcinogenesis and progression of prostate cancer. Prostate needle biopsy with PTOV1 expression in HG-PIN above a threshold of 100 should be repeated immediately for the likely presence of undiagnosed cancer.
Prostate tumor overexpressed-1 (PTOV1) was identified in our laboratory as a novel gene and protein during a screening for genes differentially expressed in prostate cancer. PTOV1 protein consists of two repeated blocks of 151 and 147 amino acids, joined by a short linker peptide, and is encoded by a 12-exon gene localized in chromosome 19q13.3 (1) . The expression of PTOV1 is regulated by androgens (2) . By immunohistochemical analysis, PTOV1 was undetectable in normal prostate tissue and benign prostate hyperplasia, whereas a strong immunoreactivity was shown in areas of carcinoma and high-grade prostatic intraepithelial neoplasia (HG-PIN). The high expression of PTOV1 in tumors correlated with their proliferative status, assessed by Ki67 immunoreactivity, and associated with nuclear localization of the protein, suggesting a functional relationship between PTOV1 overexpression, proliferative status, and nuclear localization. In cultured prostate tumor cells, PTOV1 localized in the cytoplasm of quiescent cells and after serum stimulation, the protein partially translocated to the nucleus. Exogenous overexpression of tagged-PTOV1 induced the entry of cells into the S phase of the cell cycle, which was accompanied by increased levels of cyclin D1 in the transfected cells, suggesting that overexpression of PTOV1 could contribute to the proliferative status of prostate tumor cells and thus to their biological behavior (3) .
More recently, we have observed that PTOV1 interacts with the lipid raft protein flotillin-1, and showed that protein colocalization was detected at the plasma membrane as well as in the nucleus. The depletion of PTOV1 or flotillin-1 greatly inhibited cell proliferation under basal conditions. The overexpression of PTOV1 or flotillin-1 strongly induced proliferation that was dependent on the reciprocal protein. These observations suggest that PTOV1 is able to modulate the proliferative status of cells and it requires the presence of flotillin-1 for this action (4) . Very recently, it has been observed that PTOV1 can bind to the acetyl-transferase cyclic AMPresponsive element binding protein/p300 and directly activates gene transcription (5) .
HG-PIN is defined histologically for the presence of nuclear and cytoplasmatic features similar to those of prostate cancer in glands with normal architecture (6) . The incidence of HG-PIN has been reported in 1.5% to 31% of prostate needle biopsies (7) . In early studies, using limited biopsy schemes, HG-PIN was associated with high rates of prostate cancer and it was suggested that its presence indicated an immediate repetition of the biopsy (8) . However, if a more extensive biopsy scheme is used initially, the cancer detection rate on early repeat biopsy may be considerably lower because the number of cores sampled during the initial biopsy affects the likelihood of detecting prostate cancer on the following biopsies (9) . For this reason, some investigators believe that repeated biopsies may be unnecessary in the current era and that these men can be followed using serial digital rectal examinations and prostatespecific antigen (PSA) measurements (10) . In fact, HG-PIN does not contribute to the serum concentration of PSA or modify the percentage of free PSA (11), and Loeb et al. (12) have recently suggested that PSA velocity helps to identify those men with a high likelihood of having prostate cancer and the need for repeating the biopsy.
In the present study, we analyzed the expression of PTOV1 in HG-PIN lesions associated or not associated with cancer. Because PTOV1 is significantly overexpressed in HG-PIN associated with cancer, we hypothesized that its positive detection in HG-PIN needle biopsies could be helpful in suggesting an immediate repetition of the biopsy for suspicion of cancer.
Materials and Methods
Patients characteristics. We selected specimens containing HG-PIN lesions in 140 patients according to the following classification: (a) group of true positives for PTOV1 expression in HG-PIN associated with cancer: 79 specimens from radical prostatectomies for prostate cancer; (b) group of true negatives: 11 specimens of normal prostate from radical cystoprostatectomies for bladder cancer with no associated prostate cancer; (c) study group: 50 first sextant biopsy specimens containing isolated HG-PIN lesions without concomitant cancer from January 2000 to July 2004. The patients were followed-up with at least a second repeated biopsy.
Characteristics of the study group. The characteristics of the patients are presented in Table 1 . Sixty-nine repeated biopsies were done during a mean follow-up of 12.4 months (1-39) and 11 patients (22%) were diagnosed with prostate cancer, 7 of them (63.6%) at the second biopsy, 3 (27.3%) at the third, and 1 (9.1%) at the fourth biopsy. The scheme for repeated biopsy was six peripheral zone cores plus two transition zones in 41 procedures performed until July 2004. Thereafter, a modified scheme of the Vienna nomogram was applied in 18 procedures with at least 10 peripheral zone cores plus two cores of the transition zone complemented with extended peripheral cores if necessary (13) .
Tissue microarray samples. Tissue microarrays were constructed to study the lesions present in the surgical specimens. Formalin-fixed, paraffin-embedded tissue blocks of radical prostatectomy containing HG-PIN focus near the tumor were retrieved from the archives of the Pathology Department, Vall d'Hebró n Hospital. Moreover, HG-PIN lesions in prostates from cystoprostatectomy specimens without prostate cancer were selected for the study. Three tissue cylinders of 1.2 mm of each case were punched from morphologically representative tissue areas of each donor tissue block and brought into one recipient paraffin block (3 Â 2.5 cm.), using a semiautomated tissue arrayer (Chemicon International, Inc.).
Core biopsy samples. The core biopsy studies were done in all cores with foci of HG-PIN for each patient. The prostate needle biopsies were analyzed by immunohistochemistry on complete sections from the original paraffin block.
PTOV1 antibodies. Rabbit antisera against the peptide KRRPYSD-STAKLKR of PTOV1, and its purification by affinity chromatography, have been previously described (1, 3) .
PTOV1 immunohistochemical analysis. Paraffin-embedded blocks of tissue microarrays and core biopsies were cut in 5 Am sections. Standard indirect immunoperoxidase procedures were used for immunohistochemistry (K4005, Dako Envision Plus). Sections of the tissue blocks were deparaffinized with xylene and rehydrated. Endogenous peroxidase activity was blocked with 0.2% H 2 O 2 and nonspecific labeling was avoided by incubation with a 10% goat serum solution. Sections were incubated 2 h at room temperature with anti-PTOV1 antibody (1:50 dilution). Subsequently, sections were incubated with a peroxidaselabeled secondary antibody for 30 min at room temperature. For visualization of the antigen, the sections were submerged in 3-amino-9-ethylcarbazole+ substrate-chromogen for 30 min. Slides were counterstained with hematoxylin. Human prostate cancer was used as a positive control for PTOV1 expression.
For the semiquantitative analysis, a Histo-Score (Hscore) method based on the percentage of stained cells and intensity of staining was used. Specimens were examined by phase contrast microscopy. All slides were assessed for PTOV1 expression by two trained pathologist (S. Fernández and I. de Torres). The intensity score for PTOV1 detection was defined as follows: 0, no appreciable staining; 1, weak intensity; 2, intermediate intensity; and 3, strong intensity of staining. The fraction score was based on the proportion of positively stained cells (0-100%) and the Hscore was calculated by multiplying the intensity score by the fraction score, producing a total range of 0 to 300. Finally, the mean of the Hscore from the three cores was obtained.
Statistical analysis. Quantitative variables were expressed by mean F SD and 95% confidence interval (95% CI) of the mean or median F semi-interquartile range. To compare quantitative variables, the median test and the nonparametric Mann-Whitney U test were used. To analyze distributions of qualitative variables, the Pearson m 2 test and the exact Fisher test were used. The predictors of prostate cancer were analyzed by multivariate analysis using the binary logistic regression test. The efficacy of PTOV1 detection and the selection of a threshold with clinical interest were studied by generating a receiver operating characteristic curve and analyzing the area under the curve. We also calculated the predictive values of PTOV1 and the rate of unnecessary biopsies considering a specific threshold for PTOV1. SPSS 12.0 program was used in these analyses.
Results
Expression of PTOV1 in HG-PIN lesions. Because the expression of PTOV1 is elevated in HG-PIN associated with cancer, we analyzed whether this protein could discriminate the premalignant lesions associated with cancer from the HG-PIN in prostates without cancer and if it could be used to predict the presence of cancer when malignant lesions are not detected. The expression of PTOV1 was analyzed in a mean number of 29.4 glands of HG-PIN per case of radical prostatectomy samples (the positive control group) and cystoprostatectomy samples (the negative control group). The percentage of positive radical prostatectomy cases staining with an Hscore of >100 was 89.9. Figure 1A and B show that the expression of PTOV1 in HG-PIN from radical prostatectomy samples is intense and localized both in the nucleus and cytoplasm. No significant association between the overexpression of PTOV1 and different patterns of HG-PIN were observed. In contrast, the expression of PTOV1 in the HG-PIN lesions derived from cystoprostatectomies without prostate cancer was significantly weaker and cytoplasmic (Fig. 1C and D) . These results suggested that the expression of PTOV1 in HG-PIN lesions is associated with the presence of cancer and its detection could be helpful in cancer diagnosis.
To study whether PTOV1 staining in HG-PIN is a predictor of the presence of cancer in associated lesions, we studied 50 first sextant biopsy specimens with isolated HG-PIN lesions without concurrent cancer. PTOV1 expression was evaluated in a mean of 5.5 glands per case in unifocal HG-PIN and a mean of 23.6 glands per case in multifocal HG-PIN. Figure 1E and F show representative images from the results obtained in isolated HG-PIN lesions from the group of 11 specimens in which cancer was detected in posterior biopsies. Similar to the radical prostatectomy -positive control group, the expression of PTOV1 was localized both in the nucleus and cytoplasm. In contrast, a very weak signal, exclusively localized in the cytoplasm, was observed in the HG-PIN derived from 39 patients who underwent prostate needle biopsies without cancer detected in the follow-up ( Fig. 1G and H) .
The relationship between the levels of expression of PTOV1 in the different specimens and the presence of cancer is shown in Fig. 2 . The expression of PTOV1 was semiquantitatively assessed as described in Materials and Methods and it is represented as the mean Hscore. In HG-PIN lesions associated with cancer (positive controls), the mean Hscore for PTOV1 expression was 162.6 (95% CI, 148.5-176.6) with a range between 5 and 295, and a median value of 160. In isolated HG-PIN lesions detected in cystoprostatectomy specimens (negative controls), the mean Hscore for PTOV1 expression was 67.0 (95% CI, 56.9-77.1) with a range between 40 and 90, and a median value of 65. The difference in PTOV1 expression between these two groups was significant (P < 0.001). In the HG-PIN lesions of the study group, the expression of PTOV1 was also significantly lower in patients without prostate cancer compared with those patients in whom prostate cancer was detected in the follow-up (P < 0.001). The mean of PTOV1 expression in HG-PIN lesions corresponding to the patients with prostate cancer detected in later biopsies was 151.4 (95% CI, 104. 9-197.8) , with a range between 20 and 250, and a median of 160. In contrast, the mean of PTOV1 expression in HG-PIN lesions of patients without cancer in the follow-up was 94.6 (95% CI, 74. 8-114.4) , with a range between 0 and 220, and a median of 100. There was no significant difference between the mean Hscore for PTOV1 expression in the positive control and the prostate needle biopsy group with cancer (P = 0.596). Similarly, no significant difference was detected between PTOV1 expression in the true negative group and the subset of the study group without prostate cancer in the followup (P = 0.116). These results indicate that the overexpression of PTOV1 in HG-PIN is significantly higher when these lesions are in close proximity to cancer. In addition, they indicate that HG-PIN lesions overexpressing PTOV1 may be useful in predicting the presence of cancer.
Predictors of prostate cancer in patients with isolated HG-PIN in needle biopsy. In order to analyze the predictors of prostate cancer in patients with isolated HG-PIN, we first performed a univariate analysis comparing several variables between the subset of patients in the study group with a diagnosis of prostate cancer in the follow-up and those without prostate cancer ( Table 2 ). PTOV1 expression was the only variable analyzed that showed significantly increased values in patients positive for prostate cancer during the follow-up (P = 0.001; Table 2 ). In a multivariate analysis including the same variables, PTOV1 expression was again the only independent predictor of prostate cancer with an odds ratio of 1.23 (95% CI, 1.01-1.52), again suggesting that PTOV1 might be a useful marker for prostate cancer prediction when it is detected in isolated HG-PIN lesions.
Efficacy of PTOV1 in predicting prostate cancer in patients with isolated HG-PIN in needle biopsy and search for a threshold of clinical interest. To analyze the efficacy of PTOV1 expression in predicting prostate cancer, we did a receiver operating characteristic analysis in all 140 patients with a diagnosis of prostate cancer (90) or not (50). The results are shown in Fig. 3 . The area under the curve was 0.803 (95% CI, 0.728-0.878; P < 0.001). The threshold Hscore value of 100 has a sensitivity of 90% and a specificity of 57%, and the threshold value of 63 has a sensitivity of 95% and a specificity of 38%. Applying the value 100 as the threshold for PTOV1 expression in the patients of the study group (shown in Table 3 ), we observed a sensitivity of 90.9%, a specificity of 51.3%, a positive predictive value of 34.5%, and a negative predictive value of 95.2%. In addition, the rate of 40% of negative biopsies indicates that a high number of biopsies might be avoided considering this threshold for PTOV1 expression in HG-PIN.
Discussion
This study shows that PTOV1 is significantly overexpressed in HG-PIN lesions associated with prostate cancer. This finding has allowed us to study the expression of PTOV1 in a target population of patients with isolated HG-PIN on needle biopsies and to show that HG-PIN lesions from patients positive for cancer in repeated biopsies during the follow-up, express significant higher levels of PTOV1. In addition, we observed that PTOV1 is the only independent predictor of cancer in a multivariate analysis. A threshold Hscore of 100 for PTOV1 expression provided a positive predictive value of 34.5%, whereas a negative predictive value of 95.2% indicated that 40% of biopsies might have been avoided considering the expression of PTOV1.
Our study is the first one to show that a molecular marker, overexpressed in HG-PIN lesions from prostatic core needle biopsies, enhances the detection of prostate carcinoma after initial diagnosis of HG-PIN without concurrent carcinoma. The overexpression of PTOV1 in HG-PIN that are associated with cancer provides additional evidence to link HG-PIN as a precursor lesion to prostatic adenocarcinoma. Previous results showing the correlation between the high expression of PTOV1 in tumors with higher proliferative status and the capacity of PTOV1 to induce cell entry into the S phase of the cell cycle support this notion (2, 3) . In addition, the results shown here might also suggest that a subset of HG-PIN lesions, identified by PTOV1 expression, are ''predetermined'' to develop into malignant lesions. Results from studies in isolated HG-PIN adjacent to cancer showing a higher rate of positive expression for a-methylacyl-CoA racemase compared with lesions further away from the cancer, might also support the presence of ''committed'' HG-PIN (14) . The clinical significance of an isolated HG-PIN on needle biopsy and the strategies for an early diagnosis of prostate cancer in these patients have been subjects of intense research since the formal description by McNeal and Bostwick in 1986 (15) . The detection rate of cancer after finding HG-PIN lesions on needle biopsies has decreased compared with the initial data reported in the early 1990s. The strength of the positive predictive value of HG-PIN and the clinical significance of repeated biopsies immediately or shortly after a diagnosis of isolated HG-PIN has therefore become debatable. Whereas the average risk of cancer following a diagnosis of HG-PIN in biopsy in initial studies was 50% and in some studies it reached 100% (8) , in most recent studies, the cancer detection rates on repeated biopsies after sextant sampling positive for HG-PIN ranged from 20% to 30% (16) .
The significance of an adequate sampling at the first biopsy has been also studied. Herawi et al. (9) have observed a risk of prostate cancer on repeated biopsies within 1 year of 20.8% in 332 men submitted to initial sextant biopsy scheme compared with 13.3% in 323 men with HG-PIN on a more extended initial biopsy with at least eight cores. These authors conclude that for patients diagnosed with HG-PIN on extended initial core sampling, a repeat biopsy within the first year would be unnecessary in the absence of other clinical indicators of cancer. More recently, Loeb et al. (12) , in a series of 96 men with an isolated HG-PIN in a first six-core biopsy who underwent at least one repeated biopsy showed that PSA velocity helps to identify those men who are subsequently diagnosed with cancer. They described a median for PSA velocity significantly higher in men with HG-PIN subsequently diagnosed with prostate cancer and estimated that a threshold of 0.75 ng/mL/y for PSA velocity has a positive predictive value of 45% and a negative predictive value of 84%. These authors advocate that the use of PSA velocity might help to guide the need for repeating biopsies in men with HG-PIN after 1 year of follow-up. The false-negative results on repeated biopsies over time, common to all studies mentioned, are an important issue. Lefkowitz et al. (17, 18) reported a 25.8% rate of cancer, with an interval to follow-up prostate biopsy of 3 years, studying 31 men with an initial diagnosis of HG-PIN on 12-core biopsy compared with the 2.3% rate of cancer if repeated biopsies were done within 1 year.
The 22% detection rate of cancer during the follow-up in our series was similar to the 20.8% rate observed by Bishara et al. (16) when the six-core scheme was applied to perform needle biopsies. We could not show PSA velocity as a significant predictor of cancer, as reported by Loeb et al. (12) , although in our series, the median of PSA velocity in men with cancer detected during the follow-up was 0.8, in comparison with the median of 0.08 ng/mL/y in patients without cancer on later biopsies.
The clinical usefulness of our results showing that PTOV1 expression is a good predictor of prostate cancer in men with isolated HG-PIN in biopsies, should be validated in a welldesigned prospective study that would take into account all the recent advances in the field related to this topic. NOTE: Pearson m 2 test (P = 0.012); odds ratio, 10.5 (95% CI, 1.5-90.3). The Hscore threshold of 100 was considered for the expression of PTOV1 and analyzed for the detection of cancer during follow-up in patients with isolated HG-PIN on needle biopsy. We suggest that the analysis of PTOV1 expression might be helpful in the follow-up of men with isolated HG-PIN in biopsies, especially after an extended biopsy scheme. An immediate repeated biopsy should be considered if the Hscore of PTOV1 expression is >100. If cancer is still not detected, the patient would be followed-up for his PSA velocity indicating the need to repeat the biopsy.
Conclusion
PTOV1 is a new gene and protein that is overexpressed in prostate cancer and HG-PIN, and it has a role in cancer cell proliferation. We have shown that HG-PIN lesions associated with cancer have a greater expression of PTOV1 compared with lesions not associated with cancer. In men with an isolated HG-PIN in needle biopsy, the expression of PTOV1 is a good predictor of cancer. According to our results and the data available in the literature, and considering the widespread use of extended biopsy schemes, we suggest that the overexpression of PTOV1 is a good molecular predictor of cancer to warrant an immediate repeat biopsy.
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